Back
Year : 2019 | Volume : 7 | Issue : 2 | Page : 53 - 58  


Original Articles
Human Epidermal Growth Factor Receptor 2 (HER2) as Surrogate Prognostic Marker in Gastric and Gastro Esophageal Junction Cancer

Shareefa Akhter1, Nassima Chanda2, Rumana Hamid3, Malik Tariq Rasool4

1Senior Resident, Department of Hematopathology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India

2Professor, Department of Pathology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India

3Professor, Department of Pathology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India

4Associate Professor, Radiation Oncology, Regional Cancer Centre, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar 

*Corresponding Author

Dr. Shareefa Akhter                                                                                                        

Email: malikshareefa@gmail.com                                                                                  

Abstract:

Background: HER2 is an important biomarker in gastric and gastroesophageal junction tumors. Expression of HER2 status by immunohistochemistry is heterogeneous in various patient populations. This overexpression appears to be an important prognostic factor in gastric cancer and its association with other poor prognostic factors may therefore act as a surrogate marker for poor prognosis in gastric carcinoma. We studied our patient population to look for any such association between HER2 status and various clinicopathological parameters.

Objective: To study the association between HER2 status and various clinicopathological parameters.

Methods: Patients were prospectively enrolled from August 2013 to March 2015. All relevant patient parameters were recorded. After curative resection, surgical specimens of gastric and gastroesophageal junction adenocarcinoma were analyzed for immunohistochemistry for HER2 by using standard methods. IHC score followed Hofmanns criteria. Statistical analysis of relation between HER2 status and relevant patient and disease characteristics such as gender, age at diagnosis, tumor location, histological type of tumor, stage, and size of tumor, was performed.

Results: 106 patients were enrolled into this study. Only 18 (17%) cases had HER2 score of 3+, whereas 5 (4.7%) had equivocal score (2+) and the remaining 84 (78%) tumors tested negative. HER2 status was significantly associated with location of primary tumor, gender, histopathological type of cancer, and size of primary tumor. There was no significant relation between HER2 status and age of patient, depth of invasion, nodal metastasis, or overall stage.

Conclusion: Further studies are necessary to determine the significance of HER2 status in upper gastrointestinal cancers especially that the patients need follow up where we can predict the HER2 status as an independent prognostic factor for overall survival.

Keywords: Gastric carcinoma, HER2, Pathological characteristics, Immunohistochemistry, surrogate marker





img

Important links

adv apply rec

Open Access Journal

MRIMS Journal of Health Sciences is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher of the author. This is in accordance with the BOAI definition of open access.

Visitor Count


516443
© 2019 Chandramma Education society . All Rights Reserved.